2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 295-296
Technology and Procedures, Bioinformatics, Treatment Considerations, Artificial Intelligence (AI), Deep Learning, Biological Processes, CHIP, Genomics, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Immunodeficiency, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Translational Research, MDS, Study Population, Human, Adult
PAPER

42 Recipient age remains the major predictor of outcome after 10/10 matched unrelated donor transplantation for severe aplastic anemia in adults: An EBMT saawp analysis

Regis Peffault De Latour, MD, PhD, Dirk-Jan Eikema2, Victoria Potter, MBBS, BSc, FRACP, FRCPA3, Jenny Byrne, PhD4, Georg-Nikolaus Franke Sr, MD5, John Gribben I, MD, DSc, FRCP, FMedSci, FRCPath6, Francesca Kinsella, PhD7, Beatrice Drexler, MD8, Jennifer Clay9, Inken Hilgendorf10, Thomas Schroeder, MD11, Anna Maria Raiola, MD12, Kazimierz Halaburda13, Anne Huynh, MD14, Camilla Frieri, MD, PhD15, Flore Sicre-de-Fontbrune, MD16, Joe Tuffnell17, Brian Piepenbroek18, Austin G. Kulasekararaj, MD, MBBS, FRCPath, MRCP19, Antonio M. Risitano Jr, MD, PhD20
1 Saint-Louis Hospital, Paris, France
2 EBMT Leiden Study Unit, Leiden, Netherlands
3 Kings College Hospital, London, United Kingdom
4 Nottingham University Hospitals Trust, Nottingham, United Kingdom
5 University of Leipzig Medical Center, Leipzig, Germany
6 St. Bartholomew's Hospital London, London, United Kingdom
7 Birmingham Centre for Cellular Therapy and Transplant (BCCTT), Birmingham, United Kingdom
8 University Hospital of Basel, Basel, Switzerland
9 St James University Hospital Leeds, Leeds, United Kingdom
10 Universitätsklinikum Jena, Klinik für Innere Medizin II, Jena, Germany
11 University Hospital, Essen, Germany
12 AOM – IRCCS Ospedale Policlinico San Martino. UO Ematologia e Terapie Cellulari, Genoa, Italy
13 Institute of Hematology and Transfusion Medicine, Warsaw, Poland
14 CHU de Toulouse Institut Universitaire du Cancer, Toulouse, France
15 AORN San Giuseppe Moscati Avellino, Avellino, Italy
16 Saint-Louis Hospital, Paris, France
17 EBMT Leiden Study Unit, Leiden, Netherlands
18 EBMT Leiden Study Unit, Leiden, Netherlands
19 Kings College Hospital NHS Foundation Trust, London, United Kingdom
20 University of Naples Avellino Hospital, Avellino, Italy

Introduction
Previous EBMT data identified age ≥30 years, HLA mismatch, and prolonged time from diagnosis to transplantation as the main determinants of outcome after unrelated donor HSCT for severe aplastic anemia (SAA) (Devillier et al, Haematologica 2016). As fully matched unrelated donor (10/10 HLA-MUD) transplantation is increasingly used in older adults, refining risk stratification within this subgroup has become clinically relevant. We therefore analyzed contemporary EBMT registry data to identify pre-transplant prognostic factors associated with outcomes in patients aged >30 years undergoing a first 10/10 HLA-MUD HSCT for refractory/relapsed SAA.

Methods
Adult patients (>30 years) undergoing first 10/10 HLA-MUD HSCT between 2011 and 2021 were identified from the EBMT registry. The primary endpoint was overall survival (OS). Secondary endpoints included engraftment, acute and chronic graft-versus-host disease (GVHD). GVHD-free relapse-free survival (GRFS) was defined as the time from HSCT to the last date of follow-up or event of grade III-IV acute GVHD, extensive chronic GVHD, graft failure, relapse or death. Multivariable Cox models with a centre frailty term were fitted to evaluate the effect of recipient age, conditioning regimen, stem cell source, GVHD prophylaxis, HCT-CI, interval from diagnosis to transplantation and transplant year.

Results
A total of 472 patients, transplanted across 163 EBMT centers were included. Median recipient and donor age were 50 years (IQR, 40–59) and 29 years (IQR, 24–36), respectively. The median time from diagnosis to HSCT was 11 months. Bone marrow and peripheral blood grafts were used in 46% and 54% of patients, respectively. A fludarabine-cyclophosphamide conditioning regimen was administered to 75% of patients, while ATG- and Campath-based GVHD prophylaxis were used in 58% and 32% of patients, respectively. The median follow-up was 4 years (95% CI, 3.1-4.5).Five-year OS was 67% (62%–71%). Patients aged <50 years had significantly better 5-year OS than those aged ≥50 years (72% vs 61%, respectively; p=0.005). Main causes of death were comparable between patients aged <50 and ≥50 years. Among patients who died, the most common causes of death in the two age groups were infections (47% and 46%), organ failure (6.8% and 14%), secondary malignancy (5.1% and 8.9%), GVHD (10% and 8.9%) and other causes. After adjustment, recipient age was the only factor significantly associated with OS (HR per decade, HR 1.24 [1.06–1.45]; p=0.009). Five-year GRFS was 53% (48%–58%). Recipient age was significantly associated with GRFS events after day 100 (HR per decade 1.3 [1.07–1.58]; p=0.007) but not before. Death was the predominant first GRFS event and occurred more frequently in recipients aged ≥50 years (28% vs 16% at 5 years; p=0.003), whereas graft failure as the first GRFS event was less frequent (4% vs 9%; p=0.032). Severe acute GVHD remained uncommon (7% and 4%), while extensive chronic GVHD occurred slightly more frequently in recipients aged ≥50 (10% vs 7%, p=0.07).In multivariate analysis, Campath-based GVHD prophylaxis compared with ATG was the only factor associated with a lower risk of chronic GVHD (HR 0.45 [0.25–0.80]; p=0.006) and, consequently, a lower risk of GRFS events (HR 0.61 [0.43–0.86]; p=0.005).

Conclusion
Contemporary 10/10 HLA-MUD HCT provides durable long-term survival in adults over 30 years with refractory/relapsed SAA, with approximately two-thirds of patients alive at 5 years. Recipient age remains the strongest predictor of outcome, with inferior survival beyond 50 years. Campath-based GVHD prophylaxis was associated with less chronic GVHD and improved GRFS. Novel transplantation strategies combining reduced toxicity with improved GVHD prevention are warranted to further improve outcomes, particularly in patients aged ≥50 years.

Regis Peffault De Latour, MD, PhD: MSD - Honoraria; Amgen - Honoraria; Pfizer - Honoraria; Roche - Honoraria; Jazz - Honoraria; Sanofi - Honoraria; Alexion - Honoraria; Novartis - Honoraria; Sobi - Honoraria; Pfizer - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)